Advances in sepsis diagnosis and treatment;Avanços no diagnóstico e tratamento da sepse

Jornal de Pediatria

Volumn 79, Issue SUPPL. 2, 2003, Pages

  Carvalho, Paulo R A ^a,b   Trotta, Eliana De A ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UFRGS ^*  (Brazil)

Author keywords

Critical care; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

CYTOKINE; DROTRECOGIN; PROCALCITONIN; PROTEIN C;

ACUTE PHASE RESPONSE; ADRENAL INSUFFICIENCY; ANTIBIOTIC THERAPY; CARDIOPULMONARY HEMODYNAMICS; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; INFECTION RATE; INFLAMMATORY INFILTRATE; LABORATORY TEST; MEDLINE; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0346964653     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/jped.1096     Document Type: Review

References (50)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Eng J Med 2003;348:138-50.
2. Sáez-Llorens X, McCracken GH. Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 1993;123:497-508.
3. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-1100.
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
5. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
7. Despond O, Proulx F, Carcillo JA, Lacroix J. Pediatric sepsis and multiple organ dysfunction syndrome. Curr Opin Pediatr 2001;13:247-53.
8. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
9. Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 1996;109:1033-7.
10. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Eng J Med 2003;348:1546-54.
11. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. Am J Respir Crit Care Med 2003;167:695-701.
12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
13. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995;274:968-74.
14. Leclerc F, Martinot A, Fourier C. Definitions, risk factors, and outcome of sepsis in children. In: Tibboel D, van der Voort E, editores. Update in Intensive Care and Emergency Medicine 25. Intensive care in Childhood. A Challenge to the Future. Berlin: Springer-Verlag; 1996. p. 227-38.
15. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003;326:262-6.
16. Jacobs RF, Sowell MK, Moss M, Fiser DH. Septic shock in children: bacterial etiologies and temporal relationships. Pediatr Infect Dis J 1990;9:196-200.
17. Moscovitz H, Shofer F, Mignott H, Behrman A, Kilpatric L. Plasma cytokine determination in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994;22:1102-7.
18. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intens Care Med 2001;27 Suppl:33-48.
19. Guven H, Altintop L, Baydin A, Esen S, Aygun D, Hokelec M, Doganay Z, Bek Y. Diagnostic value of procalcitonin levels as an early indicator of sepsis. Am J Emerg Med 2002;20:202-6.
20. Pettila V, Hynninnen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002;28: 1220-5.
21. Gattas DJ, Cook DG. Procalcitonin as a diagnostic test for sepsis: health technology assessment in the ICU. J Crit Care 2003;18:52-8.
22. Vincent JL, Abraham E, Annance D, Bernard G, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care 2002;6 Suppl 3:1-18.
23. Carcillo JA, Fields AI, Task Force Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002;30:1-13.
24. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
25. Rott RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, et al. Pneumonia Sepsis Study Group Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003;31:367-73.
26. Glauser MP. Pathophysiology basis of sepsis: considerations for future strategies of intervention. Crit Care Med 2000;28 Suppl:4-8.
27. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1006.
28. Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003;31:419-27.
29. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo controlled, double-blind trial. Crit Care Med 1999;27:807-14.
30. Cronin L, Cook DJ, Carlet J. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-9.
31. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
32. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of "low dose" hydrocortisone in septic shock. Am J Respir Crit Care Med 2003;167:512-20.
33. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomized controlled trial of monoclonal antibody human tumor necrosis factor in treatment of septic shock. Lancet 1998;351:929-33.
34. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997;277:1531-8.
35. Opal SM, Fisher CJ Jr, Dhainaut JFA, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-24.
36. Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1998;26:1963-71.
37. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Eng J Med 1997;336:912-8.
38. Arons MM, Wheeler AP, Bernard GR, Christman BW, Russell JA, Schein R, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Crit Care Med 1999;27:699-707.
39. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003;31:1108-12.
40. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002;13:657-70.
41. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286: 1869-78.
42. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002;88:242-52.
43. Messori A, Vacca F, Vaiani M, Tripolli S, and the Gruppo di Studio sull'antitrombina III. Antithrombin III in patients admitted to intensive care units: a multicenter observational study. Critical Care Med 2002;6:447-51.
44. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated Protein C for severe sepsis. N Engl J Med 2001;344:699-709.
45. Sollet JP, Garber GE. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. Am J Surg 2002;184(6A Suppl):11-18.
46. Cohen H, Welage LS. Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies. Pharmacotherapy 2002;22(12 Pt 2):223-35.
47. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
48. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, et al. Continuous plasmafiltration in sepsis syndrome. Crit Care Med 1999;27:2096-104.
49. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002;28:1434-9.
50. Krishnagopalan S, Dellinger RP. Innovative therapies for sepsis. BioDrugs 2001;15:645-54.